Catalyst Wire Dossier Catalyst Wire Dossier

RGN-259 ophthalmic solutions

RGN-259 ophthalmic solution · ReGenTree, LLC
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for RGN-259 ophthalmic solutions, covering 2019-10-17 to 2023-08-14. Get the full timeline:

Most recent: Clinical Trial Update: Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 [Phase 3]

See pricing